Fred Parietti, Multiply CEO and co-founder

Q&A: Through ro­bot­ics, Fred Pari­et­ti and team look to fix cell ther­a­py's fu­ture

There’s a bot­tle­neck in man­u­fac­tur­ing right now, and per­haps the cat­e­go­ry that is the best rep­re­sen­ta­tive of the is­sue is cell and gene ther­a­py. Sev­er­al com­pa­nies are try­ing dif­fer­ent things to ad­dress the is­sue, but Mul­ti­ply Labs has en­list­ed some CD­MO pow­er­hous­es on its path to­ward the au­toma­tion of the process.

Cy­ti­va and the Uni­ver­si­ty of Cal­i­for­nia-San Fran­cis­co were al­ready mem­bers of the ro­bot­ic cell ther­a­py man­u­fac­tur­ing con­sor­tium Mul­ti­ply, found­ed in 2021. Last week, it was an­nounced that Ther­mo Fish­er Sci­en­tif­ic and Charles Riv­er Lab­o­ra­to­ries have joined the team to help de­vel­op a cGMP-com­pli­ant sys­tem that can make gene-mod­i­fied cell ther­a­pies at an in­di­vid­ual scale.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.